Literature DB >> 16007684

Localization of the endothelin system in human diffuse astrocytomas.

Vinogran Naidoo1, Strinivasen Naidoo, Rajeshree Mahabeer, Deshandra M Raidoo.   

Abstract

BACKGROUND: Endothelin-1 (ET-1), a vasoconstrictor and mitogen, has recently been implicated in the pathogenesis of human glioblastoma, neuroblastoma, and meningioma. ET-1, formed by proteolysis of the propeptide big ET-1 by endothelin-converting enzyme-1 (ECE-1), mediates its cellular actions through ETA and ETB receptors. Because only immunoreactive ET-1 has been observed within human astrocytic tumor cells, the authors investigated the localization of the entire ET-1 system (ET-1 mRNA, ET-1, ECE-1, ETA and ETB receptors) in surgical samples of human diffuse astrocytomas WHO Grade II (n = 6).
METHODS: ET-1 mRNA expression was elucidated by in situ reverse transcriptase polymerase chain reaction (RT-PCR) using synthetic primers. Polyclonal antibodies were used to localize ET-1, ECE-1, ETA and ETB receptors by immunocytochemistry.
RESULTS: All ET components were detected in the six tumor samples. Intense (3+) cytoplasmic ET-1 mRNA labeling was observed in more than 75% of cells in all 6 astrocytomas. Up to 75% of tumor cells displayed intense ET-1 and ECE-1 immunolabeling distributed throughout their cytoplasm. Immunoreactive ETA and ETB receptors, observed in 25% to 75% of astrocytic tumor cells, were of moderate intensity. In addition, all components of the ET system were seen within endothelial cells of tumor blood vessels.
CONCLUSIONS: The presence of ET-1 mRNA, ECE-1, and ET-1 within tumor astrocytes suggests local ET synthesis and processing. The mitogenic and antiapoptotic properties of ET-1, as well as the vasodilatory signaling of ETB receptors, may promote tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007684     DOI: 10.1002/cncr.21277

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Expression of endothelins and their receptors in glioblastoma cell lines.

Authors:  Mayra Paolillo; Annalisa Barbieri; Patrizia Zanassi; Sergio Schinelli
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

2.  Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model.

Authors:  S Naidoo; D M Raidoo
Journal:  Metab Brain Dis       Date:  2006-07-25       Impact factor: 3.584

3.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

4.  Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.

Authors:  Shinji Nakashima; Yasuo Sugita; Hiroaki Miyoshi; Fumiko Arakawa; Hiroko Muta; Yukinao Ishibashi; Daisuke Niino; Koichi Ohshima; Mizuhiko Terasaki; Yukihiko Nakamura; Motohiro Morioka
Journal:  J Neurooncol       Date:  2015-12-08       Impact factor: 4.130

5.  Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors.

Authors:  Franziska Lange; Daniel Kaemmerer; Julianne Behnke-Mursch; Wolfgang Brück; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-25       Impact factor: 4.553

6.  Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor.

Authors:  Jennifer P Montgomery; Paul H Patterson
Journal:  BMC Cancer       Date:  2008-11-28       Impact factor: 4.430

7.  Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas.

Authors:  Marie de Tayrac; Stephan Saikali; Marc Aubry; Pascale Bellaud; Rachel Boniface; Véronique Quillien; Jean Mosser
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.